About CMS

Current Location:About CMS > Group Profile

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the “Group”) is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, dedicated to offering competitive products and services to meet China's unmet needs for health and beauty. Since 28 September 2010, the Group has been listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 867), and included in the Morgan Stanley Capital International (MSCI) China Index, Hang Seng Healthcare Index, etc. The Group is the object of transaction in both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, and also the largest shareholder of Tibet Rhodiola Pharmaceutical Holding Co. (stock code: 600211), a company listed on Shanghai Stock Exchange (A-share).

The Group focuses on innovative products that are global first-in-class, or with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems, and has built an innovative product pipeline with relatively high innovation level, good market potential and competitive differentiation advantages. Meanwhile, the Group has proven and successful experience in drug commercialization and strong capability in professional academic promotion, having created a leading market position for many existing drugs and facilitated the clinical development of innovative drugs in China.

Jointly driven by the strong product competence, the powerful academic promotion capability, and the refined internal management system, the Group has sustained rapid growth and become one of the Chinese pharmaceutical companies with the highest operating efficiency. Over the past decade (from 2011 to 2020), the compound annual growth rate (“CAGR”) of the Group’s turnover (in the case that all medicines were directly sold by the Group) was 21.2%, and the net profit CAGR was 22.8%. The Group’s ROE has maintained over 20% for 14 consecutive years.

Capitalizing on its own advantages, the Group constantly expands the business boundaries and rapidly promotes the development of new businesses, which consist of the dermatology and medical aesthetic business (CMS Aesthetics) and the healthcare business (CMS Health), while making in-depth development in multiple fields of expertise. CMS Aesthetics specializes in the development of dermatological drugs and medical aesthetic solutions, dedicated to becoming the largest and most professional company in the field of dermatology, medical aesthetics and health management in China. CMS Health stringently selects functional quality healthcare products with unique ingredients globally according to medical concept and high standards, to improve the sub-health status of Chinese consumers through one-stop cross-border e-commerce platforms.

With the prudent and professional management style and continuous performance growth, the Group has won several recognitions from the capital market: it has made Forbes lists for six times and awarded a number of honors such as the "Best Hong Kong Stock-Connect Company", "Listed Company with the Best Information Disclosure", "Best Listed Company", "Best Investment Value Award for Listed Companies", "Most Valuable Pharmaceutical Listing Company", "Best Investor Relations", "Hong Kong Stock-Connect Company with the Most Substantial Growth Potential", "Benchmarking Enterprises in Pharmaceutical Industry at the 70th Anniversary of PRC Founding", "Top 100 Innovative Pharmaceutical Enterprises in China", etc.